News & Updates
Filter by Specialty:
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.
Pioglitazone–SGLT2 inhibitor combo delivers for primary CV prevention in diabetes
09 Jun 2023
Vaccination uptake among kids in SG: Flu shots lag behind pneumococcal vax
Not enough children in Singapore are getting vaccinated against influenza, whereas the number of those who are receiving pneumococcal shots has steadily increased over time.
Vaccination uptake among kids in SG: Flu shots lag behind pneumococcal vax
08 Jun 2023
Pazopanib plus chemo improves response but not survival in advanced ovarian cancer
Treatment with pazopanib combined with chemotherapy leads to better overall response rate (ORR) in patients with recurrent or persistent ovarian cancer but falls short of improving survival, reveals a study. In addition, the combination therapy contributes to an increase in several adverse events (AEs).
Pazopanib plus chemo improves response but not survival in advanced ovarian cancer
08 Jun 2023
First-line cemiplimab improves survival in unresectable NSCLC
First-line treatment with cemiplimab, either as monotherapy or in combination with platinum-based chemotherapy, provides clinical benefits to patients with unresectable locally advanced nonsmall cell lung cancer (NSCLC) who are not candidates for definitive concurrent chemoradiation, as shown by long-term follow-up data from EMPOWER-Lung studies.
First-line cemiplimab improves survival in unresectable NSCLC
08 Jun 2023
Psychedelic drugs show promise for anxiety, depression
Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.
Psychedelic drugs show promise for anxiety, depression
08 Jun 2023
Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.
Is liposomal irinotecan superior to topotecan in relapsed small cell lung cancer?
07 Jun 2023
OPT-302 2.0 mg plus ranibizumab leads to superior vision gains in nAMD
Treatment with 2.0-mg OPT-302, a biologic inhibitor of vascular endothelial growth factor (VEGF)-C and D, in combination with ranibizumab, an anti‒VEGF-A inhibitor, results in greater vision gains when compared with the current standard of care for neovascular age-related macular degeneration (nAMD), reports a study. In addition, the combined therapy has an acceptable safety profile.